The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 23, 100169
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now?Current Opinion in Supportive & Palliative Care, 2019
- Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving SunitinibJAMA Oncology, 2019
- Cytoreductive nephrectomy in the current treatment algorithmTherapeutic Advances in Medical Oncology, 2019
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).Journal of Clinical Oncology, 2018
- Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trialThe Lancet Oncology, 2016
- Active surveillance for metastatic or recurrent renal cell carcinomaJournal of Cancer Research and Clinical Oncology, 2014
- First Experience of Active Surveillance Before Systemic Target Therapy in Patients With Metastatic Renal Cell CarcinomaUrology, 2013
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 1999